# Nurix Therapeutics (NRIX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NRIX
## Company Profile
- Ticker: NRIX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: PROTACs, Oncology, Immunology
## Stock Data
- Close: 26.63 USD
- Market cap: 1692753158.8100002 USD
- Last updated: 2026-08-12
## Business Overview
### Targeted Protein Degradation
Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies.
### Bexobrutideg
Bexobrutideg is an oral BTK degrader being advanced as a potential best-in-class therapy for relapsed or refractory chronic lymphocytic leukemia. Unlike an inhibitor, it is designed to eliminate both catalytic and scaffolding functions of the BTK protein.
### Registrational CLL Program
DAYBreak CLL-201 is a pivotal single-arm Phase 2 trial intended to support accelerated approval. DAYBreak CLL-306 is a planned randomized Phase 3 confirmatory trial comparing bexobrutideg with pirtobrutinib after prior BTK inhibitor therapy.
### Immunology Expansion
Nurix is evaluating a new bexobrutideg tablet formulation and healthy-volunteer data to support development in inflammatory and autoimmune diseases. Removing BTK may offer broader pathway suppression than conventional kinase inhibition.
### Partnered Degrader Pipeline
Partnered programs include an IRAK4 degrader in Phase 1 development and a STAT6 degrader in IND-enabling studies. Collaborations with Gilead, Sanofi and Pfizer extend the platform across multiple targets and therapeutic areas.
## Why The Stock Is Moving

As of Aug 12, 2026, NRIX closed up 2.58% at $26.63. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Phase 3 DAYBreak CLL-306 trial planned by mid-2026.
- Updated bexobrutideg clinical data at medical meetings throughout 2026.
- IND submission for bexobrutideg in immunology and inflammation targeted in 2026.

## Drug Assets

- bexobrutideg

## Recent News
- 2026-08-04 11:00 EST — [Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader](https://biopharmsignal.com/news/NRIX/nurix-announces-10-million-milestone-payment-associated-with-initiation-of-a-pha-7c23128a) — Source: Nurix Therapeutics
- 2026-08-04 05:00 EST — [Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-first-patient-enrolled-in-registrational-phase-3-da-2b8297cd) — Source: Nurix Therapeutics
- 2026-07-21 20:01 EST — [Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-hsr-clearance-of-global-collaboration-with-roche-to-2860a8c3) — Source: Nurix Therapeutics
- 2026-07-09 20:01 EST — [Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-84944bef) — Source: Nurix Therapeutics
- 2026-06-11 11:00 EST — [Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobru-e82ed85b) — Source: Nurix Therapeutics